Distinct immune “signatures” in patients who develop adverse events while receiving immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side effects, suggests a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Medical Xpress – latest medical and health news stories
